Nextida

Nextida is a biotechnology company dedicated to pioneering a new class of medicines through its proprietary molecular glue discovery platform. Launched with significant backing from ARCH Venture Partners and GV, the company focuses on identifying and developing small molecules that can induce the degradation of disease-causing proteins previously considered "undruggable." By leveraging advanced computational tools and deep biological insights, Nextida aims to address unmet needs in oncology and immunology. The company's approach centers on expanding the scope of targeted protein degradation to a broader range of therapeutic targets.